Hepatocellular carcinoma (HCC) is a highly prevalent and lethal neoplasia. Several studies have shown that HCC is the main cause of death in patients with cirrhosis. A better knowledge of the natural history of the tumor and the development of staging systems has allowed to refine the prognosis of the patients. The Barcelona Clinic Liver Cancer system (BCLC) has become the preferred staging system since it takes into account the tumor characteristics, the degree of liver impairment and the physical performance. It has been endorsed by several scientific associations and research consortia as it does not just define prognosis, but, more interestingly, it links staging with prognosis assessment and treatment recommendation. Curative therapies such as resection, transplantation and ablation can improve survival in patients diagnosed at an early HCC stage and may offer a long-term cure with overall survival that may exceed 70% at 5 years. Patients with intermediate stage HCC benefit from chemoembolization and proper selection of candidates permits a 50% survival at 3-4 years. Finally, patients diagnosed at an advanced stage benefit from sorafenib, an oral available, multikinase inhibitor with antiangiogenic and antiproliferative effects. Current research efforts are aimed at further refining prognosis prediction through molecular profiling and enhanced clinical characterization. At the same time, better knowledge of the molecular mechanisms of cancer should result in a further improvement of the current life expectancy of patients.

Keywords:
Hepatocellular carcinoma, Staging systems, Barcelona Clinic Liver Cancer, Prognosis
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics. CA Cancer J Clin 2013;63:11-30.
2.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
3.
EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
4.
Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. American Association for the Study of Liver Diseases, July 2010. Retrieved October 4, 2010, from http://www.aasld.org/practiceguidelines.
5.
Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, et al: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH), 2010 updated version. Dig Dis 2011;29:339-364.
6.
Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
7.
Verslype C, Rosmorduc O, Rougier P: Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii41-vii48.
8.
United Network for Organ Sharing Website: Organ distribution: allocation of livers-liver transplant candidates with hepatocellular carcinoma. Revised January 2013. http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf.
9.
Vilana R, Forner A, Bianchi L, Garcia-Criado A, Rimola J, de Lope CR, Reig M, et al: Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010;51:2020-2029.
10.
Chen LD, Xu HX, Xie XY, Xie XH, Xu ZF, Liu GJ, Wang Z, et al: Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol 2010;20:743-753.
11.
El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, Giordano TP: Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of US veterans. Hepatology 2009;49:116-123.
12.
Patel T: Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol 2011;8:189-200.
13.
Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, Boix L, et al: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104.
14.
Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, Massironi S, et al: The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638-644.
15.
Khalili KT, Kim TK, Jang HJ, Haider MA, Khan L, Guindi M, Sherman M: Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011;54:723-728.
16.
Sherman M: Alpha-fetoprotein: an obituary. J Hepatol 2001;34:603-605.
17.
Ishikawa K, Sasaki A, Haraguchi N, Yoshikawa Y, Mori M: A case of an α-fetoprotein-producing intrahepatic cholangiocarcinoma suggests probable cancer stem cell origin. Oncologist 2007;12:320-324.
18.
Forner A, Reig M, Bruix J: Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology 2009;137:26-29.
19.
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-755.
20.
Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, et al: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004;40:1396-1405.
21.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
22.
Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer; in Macleod CM (ed): Evaluation of Chemotherapeutic Agents. Columbia, Columbia University Press, 1949.
23.
Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338.
24.
Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
25.
Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C: A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274-1283.
26.
Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, et al: Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004;101:796-802.
27.
Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, et al: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-207.
28.
Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, et al: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastroenterology 2006;131:461-469.
29.
Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, Pompili M, et al: Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101-108.
30.
Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, et al: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27:3027-3035.
31.
N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E, Vicaut E, et al: Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009;50:1475-1483.
32.
Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, et al: A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 2010;53:108-117.
33.
Llovet JM, Peña CEA, Lathia CD, Shan M, Meinhardt G, Bruix J; Group SIS: Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:2290-2300.
34.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
35.
D'Amico G, Garcia-Tsao G, Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
36.
Kamath PS, Kim WR: The Model for End-Stage Liver Disease (MELD). Hepatology 2007;45:797-805.
37.
Rodríguez de Lope C, Tremosini S, Forner A, Reig M, Bruix J: Management of HCC. J Hepatol 2012;56(suppl):S75-S87.
38.
Forner A, Reig ME, Rodriguez de Lope C, Bruix J: Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61-74.
39.
Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK: Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010;52:380-388.
40.
Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M: Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009;104:514-524.
41.
Cho YK, Kim JK, Kim MY, Rhim H, Han JK: Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49:453-459.
42.
Lencioni R: Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-773.
43.
Llovet JM, Fuster J, Bruix J: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-1440.
44.
Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, et al: Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008;134:1908-1916.
45.
Llop E, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, Abraldes JG, et al: Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 2012;56:103-108.
46.
Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Ercolani G, Festi D, et al: Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012;256:706-712; discussion 712-703.
47.
Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M: Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl 2011;17(suppl 2):S72-S80.
48.
Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, et al: Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012;107:569-577.
49.
Burrel M, Reig M, Forner A, Barrufet M, Lope CR, Tremosini S, Ayuso C, et al: Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using DC beads. Implications for clinical practice and trial design. J Hepatol 2012;56:1330-1335.
50.
Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, Marinis A, et al: Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012;35:1119-1128.
51.
Sala M, Varela M, Bruix J: Selection of candidates with HCC for transplantation in the MELD era. Liver Transpl 2004;10:S4-S9.
52.
Varela M, Reig M, de la Mata M, Matilla A, Bustamante J, Pascual S, Turnes J, et al: Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers (in Spanish). Med Clin (Barc) 2010;134:569-576.
53.
El-Serag HB: Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
54.
Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, et al: Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851-859.
55.
Sala M, Fuster J, Llovet JM, Navasa M, Sole M, Varela M, Pons F, et al: High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004;10:1294-1300.
56.
Fuks D, Dokmak S, Paradis V, Diouf M, Durand F, Belghiti J: Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology 2012;55:132-140.
57.
Lim C, Farges O: Portal vein occlusion before major hepatectomy in patients with colorectal liver metastases: rationale, indications, technical aspects, complications and outcome. J Visc Surg 149:e86-e96.
58.
Van Lienden KP, van den Esschert JW, de Graaf W, Bipat S, Lameris JS, van Gulik TM, van Delden OM: Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol 2013;36:25-34.
59.
Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, Denys A, et al: Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208-217.
60.
Lim C, Cauchy F, Azoulay D, Farges O, Ronot M, Pocard M: Tumour progression and liver regeneration - insights from animal models. Nat Rev Gastroenterol Hepatol 2013;10:452-462.
61.
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
62.
Bismuth H, Majno PE, Adam R: Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999;19:311-322.
63.
Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, Settmacher U, et al: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080-1086.
64.
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, et al: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
65.
Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group: Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11-e22.
66.
Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, et al: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403.
67.
Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, et al: Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502-509.
68.
Volk ML, Vijan S, Marrero JA: A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008;8:839-846.
69.
Cho YK, Kim JK, Kim WT, Chung JW: Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010;51:1284-1290.
70.
Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
71.
Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171.
72.
Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, et al: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-481.
73.
Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, et al: Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497-507.e2.
74.
Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, et al: Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation. Hepatology 2011;54:868-878.
75.
Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, et al: Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52:1741-1749.
76.
Salem R, Mazzaferro V, Sangro B: Yttrium-90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges and clinical perspectives. Hepatology 2013;58:2188-2197.
77.
Beaugrand M, Sala M, Degos F, Sherman M, Bolondi L, Evans T, Trinchet J, et al: Treatment of advanced hepatocellular carcinoma by seocalcitol (a vitamin D analogue): an international randomized double-blind placebo-controlled study in 747 patients. J Hepatol 2005;42:17A.
78.
Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, et al: Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013;31:3501-3508.
79.
Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, et al: Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007;25:3069-3075.
80.
Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442.
81.
Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, Vilana R, et al: Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995;109:917-922.
82.
Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, et al: Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-58.
83.
Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE: Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007;45:9-15.
84.
Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, Yamamoto K, et al: Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011;54:532-540.
85.
Ishizuka M, Kubota K, Shimoda M, Kita J, Kato M, Park KH, Shiraki T: Effect of menatetrenone, a vitamin K2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial. Anticancer Res 2012;32:5415-5420.
86.
Riaz IB, Riaz H, Riaz T, Rahman S, Amir M, Badshah MB, Kazi AN: Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: a meta-analysis of randomized controlled trials. BMC Gastroenterol 12:170.
87.
Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S, Nishiguchi S: Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004;292:358-361.
88.
Hanahan D, Coussens LM: Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309-322.
89.
Hanahan D, Weinberg A: Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
90.
Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, et al: Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 2010;44:239-245.
91.
Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, et al: Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-474.
92.
Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, et al: Diagnosis and treatment of hepatocellular carcinoma (in Spanish). Med Clin (Barc) 2009;132:272-287.
93.
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
94.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
95.
Reig M, Rimola J, Torres F, Darnell A, Lope CR, Forner A, Llarch N, et al: Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design. Hepatology 2013;58:2023-2031.
96.
Reig M, Rodriguez de Lope C, Llarch N, Forner A, Torres F, Rios J, et al: Dermatologic adverse events within the first 60 days of sorafenib treatment are associated with better overall survival in patients with hepatocellular carcinoma. J Hepatol 2014, in press.
97.
Cheng A, Kang Y, Lin D, Park J, Kudo M, Qin S, Omata M, et al: Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011;29:abstract 4000.
98.
Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, et al: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31:3517-3524.
99.
Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, et al: Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2013;31(suppl 4):249.
100.
Zhu AX, Rosmorduc O, Evans J, Ross P, Santoro A, Carrilho FJ, Leberre M, et al: SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Ann Oncol 2012;23 (suppl 9):LBA2.
101.
Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, et al: Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2012;31:3509--3516.
102.
Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RTP, et al: EVOLVE-1: phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. J Clin Oncol 2014;32(suppl 3): 172.
103.
Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, et al: Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013;31:4067-4075.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.